Proteasomal	JJ
regulation	NN
of	IN
pulmonary	JJ
fibrosis	NN
.	.

It	PRP
is	VBZ
estimated	VBN
that	IN
,	,
combined	VBN
,	,
400,000	CD
people	NNS
are	VBP
diagnosed	VBN
with	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
or	CC
acute	JJ
lung	NN
injury/acute	NN
respiratory	JJ
distress	NN
syndrome	NN
annually	RB
in	IN
the	DT
United	NNP
States	NNPS
,	,
and	CC
both	DT
diseases	NNS
are	VBP
associated	VBN
with	IN
an	DT
unacceptably	RB
high	JJ
mortality	NN
rate	NN
.	.

Although	IN
these	DT
disorders	NNS
are	VBP
distinct	JJ
clinical	JJ
entities	NNS
,	,
they	PRP
share	VBP
pathogenic	JJ
mechanisms	NNS
that	WDT
may	MD
provide	VB
overlapping	VBG
therapeutic	JJ
targets	NNS
.	.

One	CD
example	NN
is	VBZ
fibroblast	NN
activation	NN
,	,
which	WDT
occurs	VBZ
concomitant	JJ
with	IN
acute	JJ
lung	NN
injury	NN
as	RB
well	RB
as	IN
in	IN
the	DT
progressive	JJ
fibrosis	NN
of	IN
IPF	NN
.	.

Both	DT
clinical	JJ
entities	NNS
are	VBP
characterized	VBN
by	IN
elevations	NNS
of	IN
the	DT
profibrotic	JJ
cytokine	NN
,	,
transforming	VBG
growth	NN
factor	NN
(	(
TGF	NN
)	)
-	:
beta1	NN
.	.

Protein	NN
degradation	NN
by	IN
the	DT
ubiquitin-proteasomal	JJ
system	NN
modulates	VBZ
TGF-beta1	NN
expression	NN
and	CC
signaling	NN
.	.

In	IN
this	DT
review	NN
,	,
we	PRP
highlight	VBP
the	DT
effects	NNS
of	IN
proteasomal	JJ
inhibition	NN
in	IN
various	JJ
animal	NN
models	NNS
of	IN
tissue	NN
fibrosis	NN
and	CC
mechanisms	NNS
by	IN
which	WDT
it	PRP
may	MD
regulate	VB
TGF-beta1	NN
expression	NN
and	CC
signaling	NN
.	.

At	IN
present	JJ
,	,
there	EX
are	VBP
no	DT
effective	JJ
therapies	NNS
for	IN
fibroproliferative	JJ
acute	JJ
respiratory	JJ
distress	NN
syndrome	NN
or	CC
IPF	NN
,	,
and	CC
proteasomal	JJ
inhibition	NN
may	MD
provide	VB
a	DT
novel	JJ
,	,
attractive	JJ
target	NN
in	IN
these	DT
devastating	JJ
diseases	NNS
.	.

